SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation on Thursday, January 15, 2026, at ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation on Thursday, January 15, 2026, at ...

As filed with the U.S. Securities and Exchange Commission on January 7, 2026. THE SECURITIES ACT OF 1933 Crescent Biopharma, Inc. (Exact name of registrant as specified in its charter) Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Cayman Islands 2834 06-1686563 (I.R.S. Employer Identification No.) 300 Fif ...

TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive glioblastoma models Study supports future clinical development of TTX-MC138 for patients with glioblastoma BOSTON, Jan. 6, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced can ...

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit and the expansion and persistence of Multi-Antigen Targeted T cells HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cel ...

CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept data anticipated in first quarter of 2027 Crescent partner Kelun-Biotech receives IND approval for CR-003 (SKB105) by NMPA of China Four clinical trials across portfolio expected to initiate in 2026 WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (N ...

Core Viewpoint - MAIA Biotechnology, Inc. demonstrates strong confidence in the commercial potential of ateganosine, a first-in-class anticancer treatment, as evidenced by recent stock purchases by independent directors [1][3]. Group 1: Director Investments - Three directors purchased a total of 179,737 shares and 179,737 warrants at an average price of $1.224, raising approximately $1.51 million in gross proceeds from the private placement offering [2]. - Directors and officers currently hold 5,019,857 shares, representing 13.43% of MAIA [2]. Group 2: Product Development and Trials - The initiation of a pivotal Phase 3 international trial for ateganosine has begun, with first patient dosing occurring this month [3]. - The FDA has granted Fast Track designation for ateganosine for the treatment of non-small cell lung cancer (NSCLC), indicating a high probability of regulatory approval based on statistical assessments of the trial [3]. Group 3: Mechanism of Action - Ateganosine is a telomere-targeting agent that induces telomerase-dependent DNA modification and selective cancer cell death, showing promise in advanced NSCLC treatment [4]. - The sequential treatment of ateganosine followed by PD-(L)1 inhibitors has resulted in significant tumor regression in advanced cancer models, suggesting its potential effectiveness [4]. Group 4: Company Overview - MAIA Biotechnology focuses on developing targeted immunotherapies for cancer, with ateganosine as its lead program aimed at improving treatment outcomes for patients with telomerase-positive cancer cells [5].

"I am pleased to join the Board of TransCode as the company enters an exciting stage of development. I look forward to helping advance our mission to deliver a cancer-free future for patients," said Mr. Stover. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning TransCode's technology, collaborations, and team, and statements concerning the therapeutic po ...

Core Viewpoint - Genenta Science provides an update on the ownership position of its CEO and Co-Founder, Pierluigi Paracchi, highlighting his significant investment in the company through open-market purchases of American Depositary Shares (ADSs) [1][2]. Company Ownership - Pierluigi Paracchi has acquired a total of 30,000 ADSs through open-market purchases, with no reported sales [2]. - As of December 19, 2025, Mr. Paracchi owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of Genenta's outstanding share capital [3]. Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing hematopoietic stem cell therapies for solid tumor cancers [4]. - The company's lead product candidate, Temferon™, aims to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing immune responses [4]. - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients, indicating potential for reprogramming the tumor microenvironment and inducing T cell responses [4]. - A Phase 1/2a study for metastatic Renal Cell Carcinoma has been initiated, which will explore combinations with immune checkpoint inhibitors [4]. - Genenta's therapies are designed as one-time monotherapies but may also enhance the efficacy of other approved treatments when used in combination [4].

PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 yea ...